Statistics

Total Visits

Views
Long-term 52-week results of PALACE 3, a phase 3, randomized controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement4

Select a period of time:

Number of views in the range

Views
Long-term 52-week results of PALACE 3, a phase 3, randomized controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement3

Views

Views
May 20241
June 20240
July 20241
August 20241
September 20240
October 20240
November 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States3
 

Top cities views

Views
Chicago2